Hikma Pharmaceuticals PLC has reported a solid financial performance for the first half of 2026, with revenue increasing 4% to $1.728 billion, compared to $1.658 billion in H1 2025. Growth was driven by strong performance in its Branded business, while Injectables and Hikma Rx performed in line with expectations.
The company also achieved 9% growth in core operating profit and reaffirmed its full-year 2026 guidance.
Said Darwazah, Chief Executive Officer of Hikma, said, “I am pleased to report a solid first half, with performance in line with our expectations, including 9% growth in core operating profit, and I am encouraged by the positive momentum we are seeing across the organisation.”
Also read: Integrated Digital Care Model Drives Fivefold Growth in Virtual Consultations
During the first half, Hikma completed 48 product submissions, launched 43 new products, and signed 10 strategic partnerships across the MENA region. The company also continued progress on its $250 million share buyback programme.
Hikma maintained its leadership positions globally, remaining the largest pharmaceutical company in the MENA region by sales, the seventh-largest supplier of generic medicines in the US, and the fourth-largest supplier of injectables by sales in Europe.
